PPD in the News

Evidera’s Jonca Bull comments on how cell and gene therapies hold such great promise, despite being among the most complex clinical trials in terms of design and execution.

Jan-Maarten Kroodsma and Timothy King discuss how a tailored functional service partnership model can provide expertise and flexibility for biotechnology companies.

Jürgen Hummel outlines how adaptive designs at the early stages of development can not only accelerate timelines and reduce costs, but also can help focus development on the most promising agents at the right doses in the right indications for the right patients.

Timothy King and Elisha Talley-Roithner discuss how smaller and emerging biotech companies are able to take advantage of a range of flexible outsourcing models.

PPD’s Stephen Gacheru comments on the cell and gene therapy methods he sees the industry using in the future.

PPD’s Panteli Theocharous, Janine Micheli and Catherine Vrentas outline how the application of cell and gene therapy offers the promise of significant long-term health benefits to people suffering from a wide range of diseases.

PPD’s John Maier discusses how accelerated startup and overall timelines of COVID-19 trials have presented a significant challenge to ensuring compliance with lab data integrity regulations.

PPD’s Panteli Theocharous and Fiona Thistlethwaite of The Christie NHS Foundation Trust discuss both the site and CRO role to improve the patient journey through the clinical development process, as well as the patient and product process pathway from initial referral through to follow-up.

PPD’s Panteli Theocharous and Patrick Bennett comment on the evolving nature of gene therapies.